These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 11241547

  • 1. A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).
    Pienta KJ, Fisher EI, Eisenberger MA, Mills GM, Goodwin JW, Jones JA, Dakhil SR, Crawford ED, Hussain MH.
    Prostate; 2001 Mar 01; 46(4):257-61. PubMed ID: 11241547
    [Abstract] [Full Text] [Related]

  • 2. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
    Kimura M, Sasagawa T, Tomita Y, Katagiri A, Morishita H, Saito T, Tanikawa T, Kawasaki T, Saito K, Nishiyama T, Kasahara T, Hara N, Takahashi K.
    Hinyokika Kiyo; 2003 Dec 01; 49(12):709-14. PubMed ID: 14978952
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.
    Colleoni M, Graiff C, Vicario G, Nelli P, Sgarbossa G, Pancheri F, Manente P.
    Am J Clin Oncol; 1997 Aug 01; 20(4):383-6. PubMed ID: 9256895
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ, Smith DC.
    Semin Oncol; 1997 Oct 01; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [Abstract] [Full Text] [Related]

  • 5. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
    Sumiyoshi Y, Hashine K, Nakatsuzi H, Yamashita Y, Karashima T.
    Int J Urol; 2000 Jul 01; 7(7):243-7. PubMed ID: 10910225
    [Abstract] [Full Text] [Related]

  • 6. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.
    Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, Naik H, Smith DC.
    Urology; 1997 Sep 01; 50(3):401-6; discussion 406-7. PubMed ID: 9301705
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide.
    Munshi HG, Pienta KJ, Smith DC.
    Cancer; 2001 Jun 01; 91(11):2175-80. PubMed ID: 11391599
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC, Chay CH, Dunn RL, Fardig J, Esper P, Olson K, Pienta KJ.
    Cancer; 2003 Jul 15; 98(2):269-76. PubMed ID: 12872344
    [Abstract] [Full Text] [Related]

  • 9. Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
    Dimopoulos MA, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, Constantinidis C, Kostakopoulos A, Kastriotis I, Zervas A, Aravantinos G, Dimopoulos C.
    Urology; 1997 Nov 15; 50(5):754-8. PubMed ID: 9372887
    [Abstract] [Full Text] [Related]

  • 10. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA.
    Cancer; 2002 Mar 01; 94(5):1457-65. PubMed ID: 11920502
    [Abstract] [Full Text] [Related]

  • 11. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
    Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V.
    Ann Oncol; 1999 Jan 01; 10(1):33-8. PubMed ID: 10076719
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
    Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C.
    J Clin Oncol; 1997 Sep 01; 15(9):3156-63. PubMed ID: 9294479
    [Abstract] [Full Text] [Related]

  • 13. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
    Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE.
    J Clin Oncol; 1994 Oct 01; 12(10):2005-12. PubMed ID: 7523606
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
    Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ.
    J Clin Oncol; 1999 Jun 01; 17(6):1664-71. PubMed ID: 10561202
    [Abstract] [Full Text] [Related]

  • 15. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Meluch AA, Spigel DR, Yost K, Meng C, Greco FA.
    Clin Genitourin Cancer; 2006 Mar 01; 4(4):287-92. PubMed ID: 16729913
    [Abstract] [Full Text] [Related]

  • 16. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T, Klatte T, Yap R, Kalinski T, Röpke A, Filleur S, Allhoff EP.
    BJU Int; 2006 Sep 01; 98(3):580-5. PubMed ID: 16925757
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
    Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA.
    Urology; 2001 Feb 01; 57(2):281-5. PubMed ID: 11182337
    [Abstract] [Full Text] [Related]

  • 18. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.
    Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B.
    J Clin Oncol; 1999 Oct 01; 17(10):3160-6. PubMed ID: 10506613
    [Abstract] [Full Text] [Related]

  • 19. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA, Greco FA, Morrissey LH, Raefsky EL, Steis RG, Butts JA, Hainsworth JD, Minnie Pearl Cancer Research Network.
    Cancer; 2003 Nov 15; 98(10):2192-8. PubMed ID: 14601089
    [Abstract] [Full Text] [Related]

  • 20. The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
    Samelis GF, Skarlos D, Bafaloukos D, Kosmidis P, Anagnostopoulos A, Aravantinos G, Dimopoulos MA, Hellenic Cooperative Oncology Group.
    Urology; 2003 Jun 15; 61(6):1211-5. PubMed ID: 12809899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.